Caricamento...

Compensation by the E138K Mutation in HIV-1 Reverse Transcriptase for Deficits in Viral Replication Capacity and Enzyme Processivity Associated with the M184I/V Mutations

Recently, several phase 3 clinical trials (ECHO and THRIVE) showed that E138K and M184I were the most frequent mutations to emerge in patients who failed therapy with rilpivirine (RPV) together with two nucleos(t)ide reverse transcriptase inhibitors, emtricitabine (FTC) and tenofovir (TDF). To inves...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Xu, Hong-Tao, Asahchop, Eugene L., Oliveira, Maureen, Quashie, Peter K., Quan, Yudong, Brenner, Bluma G., Wainberg, Mark A.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Microbiology 2011
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3194954/
https://ncbi.nlm.nih.gov/pubmed/21849444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/JVI.05584-11
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !